BrainStorm Cell Therapeutics has announced that it has signed a definitive agreement with the Mayo Clinic in Minnesota, USA to conduct its phase II clinical trial of NurOwn in amyotrophic lateral sclerosis (ALS), pending FDA approval. In addition, Mayo’s Human Cell Therapy Laboratory will manufacture the NurOwn cells for their clinical trial participants.
“BrainStorm’s mesenchymal stem cell-based approach is very compatible with some of the research conducted in our centre,” comments Anthony Windebank, professor of neurology and principal investigator of the study. “This trial is a logical next step in developing novel treatments for ALS which is a terrible disease with no effective treatment for our patients and their families”, he adds.
